S1 and S2

Performance and validation of an adaptable multiplex assay for detection of serologic response to SARS-CoV-2 infection or vaccination

Seroprevalence of infection-induced SARS-CoV-2 antibodies among health care users of Northern Italy: results from two serosurveys (October-November 2019 and September-October 2021)

Antiviral potential of diminazene aceturate against SARS-CoV-2 proteases using computational and in vitro approaches

Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection

Comparison of the kinetics and magnitude of antibody responses to different SARS-CoV-2 proteins in Sinopharm/BBIBP-CorV vaccinees following the BNT162b2 booster or natural infection

Poor Antibody Response to BioNTech/Pfizer Coronavirus Disease 2019 Vaccination in Severe Acute Respiratory Syndrome Coronavirus 2-Naive Residents of Nursing Homes

BioNTech/Pfizer 코로나바이러스 질병 2019 중증 급성 호흡기 증후군 코로나바이러스 백신 접종에 대한 항체 반응 불량

Identification, optimization, and biological evaluation of 3-O-β-chacotriosyl ursolic acid derivatives as novel SARS-CoV-2 entry inhibitors by targeting the prefusion state of spike protein

스파이크 단백질의 융합 전 상태를 표적으로 하는 신규 SARS-CoV-2 진입 억제제로서의 3-O-β-chacotriosyl ursolic acid 유도체의 식별, 최적화 및 생물학적 평가

The kinetics and predictors of anti-SARS-CoV-2 antibodies up to 8 months after symptomatic COVID-19: A Czech cross-sectional study

COVID-19 증상이 나타난 후 최대 8개월까지 항-SARS-CoV-2 항체의 동역학 및 예측인자: 체코 횡단 연구

Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody

Spike S2 ​​도메인 특이적 인간 중화 단일클론 항체의 직접적인 호흡기 투여에 의해 매개되는 강력한 보편적인 베타-코로나바이러스 치료 활성

The SARS-CoV-2 Nucleoprotein Induces Innate Memory in Human Monocytes

SARS-CoV-2 핵단백질은 인간 단핵구에서 선천적 기억을 유도합니다